Viking Therapeutics (VKTX) Competitors $24.57 +2.35 (+10.58%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VKTX vs. VTRS, QGEN, ASND, ROIV, LNTH, BBIO, TGTX, RVMD, LEGN, and SRPTShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Lantheus (LNTH), BridgeBio Pharma (BBIO), TG Therapeutics (TGTX), Revolution Medicines (RVMD), Legend Biotech (LEGN), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Viking Therapeutics vs. Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Lantheus BridgeBio Pharma TG Therapeutics Revolution Medicines Legend Biotech Sarepta Therapeutics Viking Therapeutics (NASDAQ:VKTX) and Viatris (NASDAQ:VTRS) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking. Does the MarketBeat Community favor VKTX or VTRS? Viking Therapeutics received 606 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 34.85% of users gave Viatris an outperform vote. CompanyUnderperformOutperformViking TherapeuticsOutperform Votes62979.92% Underperform Votes15820.08% ViatrisOutperform Votes2334.85% Underperform Votes4365.15% Does the media favor VKTX or VTRS? In the previous week, Viatris had 28 more articles in the media than Viking Therapeutics. MarketBeat recorded 55 mentions for Viatris and 27 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 1.03 beat Viatris' score of -0.02 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 13 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 1 Very Positive mention(s) 7 Positive mention(s) 39 Neutral mention(s) 2 Negative mention(s) 5 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of VKTX or VTRS? 76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 4.7% of Viking Therapeutics shares are owned by insiders. Comparatively, 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher earnings & valuation, VKTX or VTRS? Viatris has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViking TherapeuticsN/AN/A-$109.96M-$1.00-24.19Viatris$14.74B0.61$54.70M-$0.53-14.17 Which has more volatility & risk, VKTX or VTRS? Viking Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Do analysts rate VKTX or VTRS? Viking Therapeutics presently has a consensus price target of $89.75, suggesting a potential upside of 271.02%. Viatris has a consensus price target of $10.50, suggesting a potential upside of 39.81%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Viking Therapeutics is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92Viatris 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Is VKTX or VTRS more profitable? Viking Therapeutics has a net margin of 0.00% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat Viking Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viking TherapeuticsN/A -11.93% -11.57% Viatris -5.87%16.46%7.09% SummaryViking Therapeutics and Viatris tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.72B$6.33B$5.32B$7.55BDividend YieldN/A3.20%5.11%4.34%P/E Ratio-24.196.7421.6317.69Price / SalesN/A223.59372.9293.19Price / CashN/A65.6738.1534.64Price / Book6.955.786.373.94Net Income-$109.96M$141.32M$3.20B$247.32M7 Day Performance13.67%3.44%5.06%4.90%1 Month Performance-21.69%-14.28%-7.61%-6.61%1 Year Performance-64.75%-16.23%7.03%-2.70% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics4.2689 of 5 stars$24.57+10.6%$89.75+265.3%-67.6%$2.76BN/A-24.5720Positive NewsGap UpHigh Trading VolumeVTRSViatris2.7588 of 5 stars$7.64+0.2%$10.50+37.5%-33.5%$9.09B$14.74B-10.2937,000QGENQiagen3.4677 of 5 stars$40.44+5.7%$47.71+18.0%+7.5%$8.96B$1.98B112.296,030ASNDAscendis Pharma A/S2.2484 of 5 stars$138.70-2.8%$204.64+47.5%+3.4%$8.39B$363.64M-19.471,017Positive NewsROIVRoivant Sciences2.5436 of 5 stars$9.22-2.6%$17.50+89.9%-9.9%$6.56B$122.59M-61.32860Positive NewsGap DownLNTHLantheus4.3905 of 5 stars$94.35+3.8%$129.43+37.2%+67.8%$6.44B$1.53B15.64700Positive NewsBBIOBridgeBio Pharma4.5176 of 5 stars$30.82-1.8%$52.64+70.8%+26.4%$5.85B$221.90M-10.78400Positive NewsTGTXTG Therapeutics3.2698 of 5 stars$37.05-0.8%$40.67+9.8%+159.3%$5.80B$329.00M-369.14290Positive NewsRVMDRevolution Medicines3.6854 of 5 stars$31.12-0.6%$65.23+109.6%-1.0%$5.76B$742,000.00-8.63250Positive NewsGap UpLEGNLegend Biotech2.3489 of 5 stars$30.07-6.1%$79.00+162.8%-39.5%$5.51B$627.24M-31.571,070Positive NewsGap UpSRPTSarepta Therapeutics4.6816 of 5 stars$52.86-2.9%$163.18+208.7%-58.5%$5.12B$1.90B42.23840 Remove Ads Related Companies and Tools Related Companies Viatris Competitors Qiagen Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Lantheus Competitors BridgeBio Pharma Competitors TG Therapeutics Competitors Revolution Medicines Competitors Legend Biotech Competitors Sarepta Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VKTX) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersThe biggest story CNBC isn't talking about (yet)This Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDeFi Coin on Verge of Breakout!Crypto’s down — but the fundamentals aren’t. Strategic investors are using this dip to scoop up undervalued...Crypto 101 Media | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VKTX Stock Free VKTX Stock Alerts